Tyrosine kinase inhibitorFDA-approvedFirst-line
Alectinib
How it works
Blocks the anaplastic lymphoma kinase (ALK) on cancer cells, preventing them from growing and dividing.
Cancer types
Lung Cancer— ALK-positive
Efficacy
In clinical trials, around 80% of ALK-positive patients achieved an objective response, with median progression-free survival of approximately 11 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Alectinib's Side Effects Linked to Biotin Deficiency | Lung Cancer | lab-study | — | Source → |
| Combining Alectinib and Cobimetinib to Treat Advanced Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Lorlatinib Cost-Effective for Lung Cancer Patients in Italy | Lung Cancer | phase-3 | Lorlatinib provided higher benefits (+2.01 life-years; +1.66 quality-adjusted life-years) at lower costs (-€19,210 per patient) compared to alectinib. | Source → |
| Alectinib and Genetic Variations in Non-Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Researchers Explore How Immune Cells Affect Lung Cancer Treatment | Lung Cancer | observational | Progression-free survival on alectinib appeared longer in patients with high than in those with low CD8A expression; however, this difference was not statistically conclusive (HR, 0.49 [95% CI, 0.18-1.35]). | Source → |
| Study of Alectinib as Adjuvant Therapy for Early Stage Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Alectinib Shows Benefit in Early-Stage Lung Cancer Treatment | Lung Cancer | phase-3 | Patients receiving alectinib had longer DFS versus those who received chemotherapy. | Source → |
| Alectinib Treatment Effective for Some Lung Cancer Patients | Lung Cancer | observational | The median maximum tumor reduction rates were 90.5% for patients with V1, 63.4% for patients with V2, and 98.0% for patients with V3. | Source → |
| Alectinib Therapy for Lung Cancer: A Single Case Study | Lung Cancer | observational | — | Source → |
| Comparing Two Cancer Treatments in Lung Cancer Patients | Lung Cancer | observational | The 3-year progression-free survival rate was 51.5% for brigatinib and 62.1% for alectinib. | Source → |
| Combining Cancer Treatments Increases Risk of Lung Damage | Lung Cancer | observational | — | Source → |
| Researchers Report a Rare Case of Cancer Remission in Stage IV Lung Cancer Patient | Lung Cancer | observational | — | Source → |
| Alectinib Shows Longer Survival in Asian Patients with Advanced Lung Cancer | Lung Cancer | phase-3 | Median progression-free survival was 41.6 months with alectinib versus 11.1 months with crizotinib. | Source → |
| Rare Liver Problem in Lung Cancer Patients Taking Alectinib | Lung Cancer | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.